Independent research has revealed that a new drug can decrease the spread of colon cancer to the liver by approximately 50 per cent.
Australia’s natural human antibody therapy company, Patrys Limited (ASX: PAB), announced on 16 September that lead product PAT-SM6 effectively prevented colon cancer metastases in a series of recently completed preclinical animal studies.
PAT-SM6, which will be tested in a first-in-human clinical trial expected to commence this calendar year, represents one of the many promising antibodies in Patrys’ therapeutic product pipeline.
The recently completed studies were conducted by independent researchers and were designed to test PAT-SM6’s ability to prevent the metastatic spread of colon cancer to the liver.
In the 19 animals treated with PAT-SM6, the median number of tumours that spread from the colon to the liver was decreased by approximately 50 per cent as compared to the corresponding control group. This statistically significant result demonstrates the promise of PAT-SM6 as an effective treatment for the prevention of colon cancer metastases.
Dr. Frank Hensel, Patrys’ Vice President, Research and Development, added “the result of these studies reinforces earlier reported results where PAT-SM6 showed the ability to prevent the spread of gastric cancer in preclinical animal studies. Looking forward, the ability of PAT-SM6 to consistently perform in these studies across a number of different cancers gives our team added confidence in the endpoints we hope to achieve in the upcoming human clinical trial for PAT-SM6.”
Australia’s natural human antibody therapy company, Patrys Limited (ASX: PAB), announced on 16 September that lead product PAT-SM6 effectively prevented colon cancer metastases in a series of recently completed preclinical animal studies.
PAT-SM6, which will be tested in a first-in-human clinical trial expected to commence this calendar year, represents one of the many promising antibodies in Patrys’ therapeutic product pipeline.
The recently completed studies were conducted by independent researchers and were designed to test PAT-SM6’s ability to prevent the metastatic spread of colon cancer to the liver.
In the 19 animals treated with PAT-SM6, the median number of tumours that spread from the colon to the liver was decreased by approximately 50 per cent as compared to the corresponding control group. This statistically significant result demonstrates the promise of PAT-SM6 as an effective treatment for the prevention of colon cancer metastases.
Dr. Christoph Otto, a medical oncologist and one of the lead investigators for the preclinical studies, said “the results of these studies indicate that PAT-SM6 offers great potential in terms of preventing colon cancer metastases, which is critically important because in most cases it is the spread of colon cancer to other organs that ultimately kills the patient.”
“Products with this type of therapeutic potential are in high demand from the medical community given that currently approved cancer treatments are largely ineffective at preventing such metastases,” added Dr. Otto. Dr. Frank Hensel, Patrys’ Vice President, Research and Development, added “the result of these studies reinforces earlier reported results where PAT-SM6 showed the ability to prevent the spread of gastric cancer in preclinical animal studies. Looking forward, the ability of PAT-SM6 to consistently perform in these studies across a number of different cancers gives our team added confidence in the endpoints we hope to achieve in the upcoming human clinical trial for PAT-SM6.”
